Jefferies Group reiterated their buy rating on shares of Forward Pharma A/S (NASDAQ:FWP) in a research report sent to investors on Tuesday morning. The firm currently has a $40.00 price objective on the stock.
Separately, Zacks Investment Research upgraded Forward Pharma A/S from a sell rating to a hold rating in a research report on Friday, July 1st.
Forward Pharma A/S (NASDAQ:FWP) remained flat at $20.71 during trading on Tuesday. 122 shares of the stock were exchanged. The company’s market capitalization is $971.96 million. The stock’s 50 day moving average is $20.53 and its 200 day moving average is $19.37. Forward Pharma A/S has a 52 week low of $11.22 and a 52 week high of $29.41.
Forward Pharma A/S (NASDAQ:FWP) last released its earnings results on Thursday, September 1st. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.26) by $0.06. On average, equities analysts forecast that Forward Pharma A/S will post ($1.46) EPS for the current fiscal year.
Several hedge funds have recently added to or reduced their stakes in FWP. Iguana Healthcare Management LLC purchased a new stake in Forward Pharma A/S during the first quarter valued at $494,000. Motley Fool Wealth Management LLC increased its stake in Forward Pharma A/S by 10.2% in the first quarter. Motley Fool Wealth Management LLC now owns 64,231 shares of the company’s stock valued at $1,092,000 after buying an additional 5,940 shares during the last quarter. Sabby Management LLC increased its stake in Forward Pharma A/S by 9.7% in the first quarter. Sabby Management LLC now owns 76,785 shares of the company’s stock valued at $1,305,000 after buying an additional 6,785 shares during the last quarter. Perceptive Advisors LLC increased its stake in Forward Pharma A/S by 67.1% in the second quarter. Perceptive Advisors LLC now owns 311,400 shares of the company’s stock valued at $5,658,000 after buying an additional 125,100 shares during the last quarter. Finally, BlueMountain Capital Management LLC increased its stake in Forward Pharma A/S by 21.9% in the first quarter. BlueMountain Capital Management LLC now owns 1,344,495 shares of the company’s stock valued at $22,856,000 after buying an additional 241,571 shares during the last quarter.
Forward Pharma A/S Company Profile
Forward Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in the development of FP187, a formulation of dimethyl fumarate (DMF) for the treatment of several inflammatory and neurological indications, including multiple sclerosis (MS). The Company’s clinical candidate, FP187, is under development for the treatment of relapsing remitting MS (RRMS) and other immune disorders, such as psoriasis.
Receive News & Ratings for Forward Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forward Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.